Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-002800
Filing Date
2017-01-06
Accepted
2017-01-06 21:03:19
Documents
1
Period of Report
2017-01-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3936
  Complete submission text file 0001209191-17-002800.txt   5417
Mailing Address 1616 EASTLAKE AVE. E SUITE 310 SEATTLE WA 98102
Business Address 1616 EASTLAKE AVE. E SUITE 310 SEATTLE WA 98102 (206) 682-0645
Immune Design Corp. (Issuer) CIK: 0001437786 (see all company filings)

EIN.: 262007174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E, SUITE 310 SEATTLE WA 98102
Business Address
Svennilson Peter (Reporting) CIK: 0001606074 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36561 | Film No.: 17515591